ENDRA Life Sciences Inc.
NDRA
$6.46
$1.1922.58%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 113.04% | -26.55% | 23.62% | 32.20% | 45.01% |
| Total Depreciation and Amortization | 19.51% | -12.94% | -14.87% | -27.04% | -34.53% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -4,498.13% | 11.67% | -34.68% | -52.85% | -44.95% |
| Change in Net Operating Assets | -9.66% | 1,803.03% | -116.01% | 91.60% | 11.86% |
| Cash from Operations | 16.71% | 13.41% | -6.33% | 29.76% | 46.54% |
| Capital Expenditure | -- | -- | -- | -- | -100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 2,701.16% | -- | -- | -100.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 354.15% | 80.86% | 246.81% | -- | -88.32% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 354.15% | 80.86% | -- | 8,694.12% | -88.32% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2,122.43% | 65.15% | 97.91% | 38.72% | -104.87% |